Home › NDC Lookup › Ingredients › Sodium Bicarbonate › 51662-1573-03
SODIUM BICARBONATE 84 mg/mL Injection, Solution — NDC 51662-1573-03 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

SODIUM BICARBONATE 84 mg/mL Injection, Solution — NDC 51662-1573-3 (Billing 51662-1573-03)

by HF Acquisition Co LLC, DBA HealthFirst · 25 POUCH in 1 CASE / 1 VIAL, SINGLE-DOSE in 1 POUCH / 50 mL in 1 VIAL, SINGLE-DOSE

This is a package of SODIUM BICARBONATE 84 mg/mL Injection, Solution from HF Acquisition Co LLC, DBA HealthFirst, marketed since Feb 2022 and currently FDA-listed.

NDC 51662-1573-03
🏷️ FDA NDC (as labeled) 51662-1573-3 billing pads the package segment with a zero
This package
Contains50 mL in 1 vial, single-dose Pack sizes2 compare ↓
Product page 51662-1573-01 Also comes in: 50 ml 51662-1573-1
Rx only On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Sodium Bicarbonate (different manufacturers) — 5 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 4, 2025 — Lack of Assurance of Sterility. (PFIZER INC) · FDA recall D-0591-2025
Class II · Jul 30, 2025 — Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested. (Exela Pharma Sciences LLC) · FDA recall D-0620-2025
Class II · Mar 7, 2025 — Lack of Assurance of Sterility (Exela Pharma Sciences LLC) · FDA recall D-0303-2025
Class I · Dec 21, 2023 — Presence of Particulate Matter; identified as glass (Pfizer Inc.) · FDA recall D-0234-2024
Class I · Oct 18, 2023 — Presence of Particulate Matter: Silicone (Exela Pharma Sciences LLC) · FDA recall D-0116-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 51662-1573-3
Product NDC 51662-1573
11-digit billing NDC 51662157303
RxCUI 1868486
UNII 8MDF5V39QO
SPL Set ID d8516f38-6f92-32d1-e053-2995a90a96bf
Mechanism of action Alkalinizing Activity
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG OTHER
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-02-18
Route INTRAVENOUS
Dosage form INJECTION, SOLUTION
Substance SODIUM BICARBONATE
Quick answers
  • RxCUI (RxNorm): 1868486
Why two NDCs? The FDA registers this code as 51662-1573-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 51662-1573-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Salt solutions class.

Drug family (ATC) Salt solutions, Electrolyte solutions
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📗 Our plain-language guide HelloPharmacist
  • It depends on the product. By mouth, it relieves heartburn, sour stomach and acid indigestion. On the skin, some products ease itching from insect bites and poison ivy. The injecti...
  • Labels for products like Rapidol and De La Cruz Sodium Bicarbonate Antacid say to dissolve it completely in water and drink it. It can be repeated every couple of hours up to a dai...
  • Don't use the maximum dose for more than 2 weeks unless a doctor tells you to. If your symptoms last longer than 2 weeks, stop and see your doctor.
  • Antacids can interact with some prescription drugs. Please check with me or your doctor before using it if you take any.
📖 Read our full Sodium Bicarbonate guide →
4
Nutrient depletion considerations

Sodium Bicarbonate (OTC Drug) may be associated with lower levels of 4 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Sodium Bicarbonate (OTC Drug) nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 50 ml
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
51662-1573-01 51662-1573-1 Main listing 50 mL in 1 VIAL, SINGLE-DOSE 2022-02-18 — Active
51662-1573-03 You're viewing this 25 POUCH in 1 CASE / 1 VIAL, SINGLE-DOSE in 1 POUCH / 50 mL in 1 VIAL, SINGLE-DOSE 2022-07-31 — Active

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 25 pouch in 1 case / 1 vial, single-dose in 1 pouch / 50 ml in 1 vial, single-dose.
What NDC number is used to bill for this package of SODIUM BICARBONATE 84 mg/mL Injection, Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Sodium Bicarbonate 84 mg/mL 00409-6625-14 Hospira, 25 vials $0.154 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 51754-5001-04 Exela 25 vials $0.154 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 51754-8888-04 Exela 25 vials $0.154 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 63323-0089-50 Fresenius 25 vials $0.154 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 68462-0951-65 Glenmark 25 vials $0.154 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 70095-0050-03 Sun 25 vials $0.154 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 72603-0209-25 NORTHSTAR 25 vials $0.154 AP Discontinued —
Sodium Bicarbonate 84 mg/mL 72572-0740-20 Civica 20 vials $0.159 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 81298-7620-03 Long 20 vials $0.159 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 81665-0200-05 OMNIVIUM 20 vials $0.159 AP Availability likely —
Sodium Bicarbonate 84 mg/mL 00404-9980-50 Henry 1 vial — — FDA listed —
Sodium Bicarbonate 84 mg/mL 50090-0530-00 A-S 50 ml — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 50090-6813-00 A-S 1 vial — AP FDA listed —
8.4% Sodium Bicarbonate 84 mg/mL 51662-1256-01 HF 50 ml — — FDA listed —
Sodium Bicarbonate 84 mg/mLthis 51662-1573-03 HF 25 pouches — — FDA listed —
Sodium Bicarbonate 84 mg/mL 71872-7247-01 Medical 1 vial — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 71872-7310-01 Medical 1 vial — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 71872-7371-01 Medical 1 vial — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 71872-7376-01 Medical 1 vial — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 72162-2314-02 Bryant 20 vials — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 80830-2305-02 Amneal 25 vials — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 82449-0000-05 Steriscience 20 vials — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 83854-0001-20 Anthea 20 vials — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 84549-0050-03 ProPharma 50 ml — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 51754-5011-04 Exela 25 vials — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 76329-3352-01 International 1 syringe — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 71872-7097-01 Medical 1 syringe — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 71872-7266-01 Medical 1 syringe — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 84549-0352-01 ProPharma 50 ml — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 70518-4158-00 REMEDYREPACK 1 syringe — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 51662-1383-01 HF 1 syringe — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 51662-1255-01 HF 1 syringe — — FDA listed —
Sodium Bicarbonate 84 mg/mL 00409-6637-14 Hospira, 1 syringe — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 71357-0004-10 Milla 10 vials — AP FDA listed —
Sodium Bicarbonate 84 mg/mL 51754-8020-04 Exela 25 vials — AP FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
Feb 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 142M471B3J
    Carbon dioxide is a colorless gas used in medicines as a propellant in pressurized inhalers and aerosol sprays to help deliver the active medication to where it's needed.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

2 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerHF Acquisition Co LLC, DBA HealthFirst
Labeler code51662
First marketedFeb 2022
Product typeHuman Prescription Drug
Portfolio333 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 210 words ▾

INDICATIONS & USAGE Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments.

Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis — e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself.

Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial — e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis.

⏱️ Dosage and Administration ~2 min read ▾

DOSAGE & ADMINISTRATION Sodium Bicarbonate Injection, USP is administered by the intravenous route. In cardiac arrest, a rapid intravenous dose of 200 to 300 mEq of bicarbonate, given as a 4.2% or 8.4% solution is suggested for adults. Cautions should be observed in emergencies where very rapid infusion of large quantities of bicarbonate is indicated.

Bicarbonate solutions are hypertonic and may produce an undesirable rise in plasma sodium concentration in the process of correcting the metabolic acidosis. In cardiac arrest, however, the risks from acidosis exceed those of hypernatremia. In infants (up to two years of age), intravenous administration at a dose not to exceed 8 mEq/kg/day is recommended.

Slow administration rates and a solution of 4.2% are recommended in neonates, to guard against the possibility of producing hypernatremia, decreasing cerebrospinal fluid pressure and inducing intracranial hemorrhage. In less urgent forms of metabolic acidosis, Sodium Bicarbonate Injection, USP may be added to other intravenous fluids. The amount of bicarbonate to be given to older children and adults over a four- to eight- hour period is approximately 2 to 5 mEq/kg of body weight — depending upon the severity of the acidosis as judged by the lowering of total CO 2 content, blood pH and clinical condition of the patient.

Bicarbonate therapy should always be planned in a stepwise fashion since the degree of response from a given dose is not precisely predictable. Initially an infusion of 2 to 5 mEq/kg body weight over a period of 4 to 8 hours will produce a measurable improvement in the abnormal acidbase status of the blood. The next step of therapy is dependent upon the clinical response of the patient.

If severe symptoms have abated, then the frequency of administration and the size of the dose may be reduced. In general, it is unwise to attempt full correction of a low total CO 2 content during the first 24 hours of therapy, since this may be accompanied by an unrecognized alkalosis because of a delay in the readjustment of ventilation to normal. Owing to this lag, the achievement of total CO 2 content of about 20 mEq/liter at the end of the first day of therapy will usually be associated with a normal blood pH.

Further modification of the acidosis to completely normal values usually occurs in the presence of normal kidney function when and if the cause of the acidosis can be controlled. Values for total CO 2 which are brought to normal or above normal within the first day of therapy are very likely to be associated with grossly alkaline values for blood pH, with ensuing undesired side effects. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

See PRECAUTIONS . Do not use unless solution is clear and the container or seal is intact. Discard unused portion.

⛔ Contraindications 31 words ▾

CONTRAINDICATION Sodium Bicarbonate Injection, USP is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction, and in patients receiving diuretics known to produce a hypochloremic alkalosis.

⚠️ Warnings 86 words ▾

WARNINGS Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.

Extravascular infiltration should be avoided, see ADVERSE REACTIONS .

🤒 Adverse Reactions 78 words ▾

ADVERSE REACTIONS Overly aggressive therapy with Sodium Bicarbonate Injection, USP can result in metabolic alkalosis (associated with muscular twitchings, irritability and tetany) and hypernatremia. Inadvertent extravasation of intravenously administered hypertonic solutions of sodium bicarbonate have been reported to cause chemical cellulitis because of their alkalinity, with tissue necrosis, ulceration or sloughing at the site of infiltration. Prompt elevation of the part, warmth and local injection of lidocaine or hyaluronidase are recommended to prevent sloughing of extravasated IV infusions.

🆘 Overdosage 75 words ▾

OVERDOSAGE Should alkalosis result, the bicarbonate should be stopped and the patient managed according to the degree of alkalosis present. 0.9% sodium chloride injection intravenous may be given; potassium chloride also may be indicated if there is hypokalemia. Severe alkalosis may be accompanied by hyperirritability or tetany and these symptoms may be controlled by calcium gluconate.

An acidifying agent such as ammonium chloride may also be indicated in severe alkalosis. See WARNINGS and PRECAUTIONS .

🧬 Clinical Pharmacology 189 words ▾

CLINICAL PHARMACOLOGY Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis. Sodium bicarbonate in water dissociates to provide sodium (Na +) and bicarbonate (HCO 3-) ions. Sodium (Na +) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances.

Bicarbonate (HCO 3-) is a normal constituent of body fluids and the normal plasma level ranges from 24 to 31 mEq/liter. Plasma concentration is regulated by the kidney through acidification of the urine when there is a deficit or by alkalinization of the urine when there is an excess. Bicarbonate anion is considered “labile” since at a proper concentration of hydrogen ion (H +) it may be converted to carbonic acid (H 2C0 3) and thence to its volatile form, carbon dioxide (CO 2) excreted by the lung.

Normally a ratio of 1:20 (carbonic acid: bicarbonate) is present in the extracellular fluid. In a healthy adult with normal kidney function, practically all the glomerular filtered bicarbonate ion is reabsorbed; less than 1% excreted in the urine.

📦 How Supplied / Storage and Handling 117 words ▾

HOW SUPPLIED SODIUM BICARBONATE INJECTION, USP is supplied in the following dosage forms. NDC 51662-1573-1 SODIUM BICARBONATE INJECTION, USP, 8.4% 50 mEq (1 mEq PER mL) 50mL VIAL NDC 51662-1573-2 SODIUM BICARBONATE INJECTION, USP, 8.4% 50 mEq (1 mEq PER mL) 50mL VIAL IN A POUCH NDC 51662-1573-3 SODIUM BICARBONATE INJECTION, USP, 8.4% 50 mEq (1 mEq PER mL) 50mL VIAL IN A POUCH, 25 POUCHES IN A CASE Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Also supplied in the following manufacture supplied dosage forms, Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

HF Acquisition Co LLC, DBA HealthFirst 11629 49th Pl W. Mukilteo, WA 98275

📋 Description 138 words ▾

DESCRIPTION Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic, hypertonic solution of Sodium Bicarbonate (NaHCO 3), USP, in Water for Injection for administration by the intravenous route as an electrolyte replenisher and systemic alkalizer. pH of the solution is 7.0 to 8.5. Solutions are offered in concentrations of 4.2% and 8.4%. See table in HOW SUPPLIED/STORAGE AND HANDLING section for contents and characteristics.

The solutions contain no bacteriostat, antimicrobial agent or added buffer and are intended only for use as a single-dose injection. When smaller doses are required, the unused portion should be discarded with the entire unit. Sodium Bicarbonate, 84 mg is equal to one milliequivalent each of Na + and HCO 3-.

Sodium Bicarbonate, USP is chemically designated NaHCO 3, a white crystalline powder soluble in water. Water for Injection, USP is chemically designated H 2O.

⚠️ Precautions ~2 min read ▾

PRECAUTIONS The potentially large loads of sodium given with bicarbonate require that caution be exercised in the use of sodium bicarbonate in patients with congestive heart failure or other edematous or sodium retaining states, as well as in patients with oliguria or anuria. See table in HOW SUPPLIED/STORAGE AND HANDLING section for amounts of sodium present in solutions. Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.

Potassium depletion may predispose to metabolic alkalosis and coexistent hypocalcemia may be associated with carpopedal spasm as the plasma pH rises. These dangers can be minimized if such electrolyte imbalances are appropriately treated prior to or concomitantly with bicarbonate infusion. Rapid injection (10 mL/min.) of hypertonic Sodium Bicarbonate Injection, USP, solutions into neonates and children under two years of age may produce hypernatremia, a decrease in cerebrospinal fluid pressure and possible intracranial hemorrhage.

The rate of administration in such patients should therefore be limited to no more than 8 mEq/kg/day. A solution diluted to 4.2% may be preferred for such slow administration. In emergencies such as cardiac arrest, the risk of rapid infusion must be weighed against the potential for fatality due to acidosis.

Drug Interactions Additives may be incompatible; norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established. Precipitation or haze may result from sodium bicarbonate-calcium admixtures.

Note: Do not use the injection if it contains precipitate. Additives may be incompatible. Consult with pharmacist, if available.

When introducing additives, use aseptic technique, mix throughly and do not store. Laboratory Tests The aim of all bicarbonate therapy is to produce a substantial correction of the low total CO 2 content and blood pH, but the risks of overdosage and alkalosis should be avoided. Hence, repeated fractional doses and periodic monitoring by appropriate laboratory tests are recommended to minimize the possibility of overdosage.

Pregnancy Category C: Animal reproduction studies have not been conducted with sodium bicarbonate. It is also not known whether sodium bicarbonate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium bicarbonate should be given to a pregnant woman only if clearly needed.

📄 Package Label / Principal Display Panel 49 words ▾

PRINCIPAL DISPLAY PANEL - VIAL LABEL VIAL LABEL VIAL LABEL

PRINCIPAL DISPLAY PANEL - 51662-1573-1 SERIALIZED LABELING 51662-1573-1 SERIALIZED LABELING Label

NDC 51662-1573-2 POUCH LABELING NDC 51662-1573-2 POUCH LABELING VIAL LABEL Label VIAL LABELING (POUCH)

NDC 51662-1573-3 CASE LABELING NDC 51662-1573-3 CASE LABELING SERIALIZED RFID LABELING Label RFID Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Sodium Bicarbonate — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Sodium Bicarbonate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$136.8K
Claims incl. refills
2.2K
Beneficiaries
722
Spend / beneficiary
$189.50
Spend / claim
$61.05
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product Marketed without an FDA application

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by HF Acquisition Co LLC, DBA HealthFirst. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 50 ml (51662-1573-01). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
HF Acquisition Co LLC, DBA HealthFirst is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 51662-1572-01 · HF 51662-1574-01 · HF →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.